Amyloid-Degrading Enzymes as Therapeutic Targets in Alzheimers Disease

Author(s): Natalia N. Nalivaeva, Lilia R. Fisk, Nikolai D. Belyaev, Anthony J. Turner

Journal Name: Current Alzheimer Research

Volume 5 , Issue 2 , 2008

Become EABM
Become Reviewer
Call for Editor


The steady state concentration of the Alzheimers amyloid-β peptide in the brain represents a balance between its biosynthesis from the transmembrane amyloid precursor protein (APP), its oligomerisation into neurotoxic and stable species and its degradation by a variety of amyloid-degrading enzymes, principally metallopeptidases. These include, among others, neprilysin (NEP) and its homologue endothelin-converting enzyme (ECE), insulysin (IDE), angiotensinconverting enzyme (ACE) and matrix metalloproteinase-9 (MMP-9). In addition, the serine proteinase, plasmin, may participate in extracellular metabolism of the amyloid peptide under regulation of the plasminogen-activator inhibitor. These various amyloid-degrading enzymes have distinct subcellular localizations, and differential responses to aging, oxidative stress and pharmacological agents and their upregulation may provide a novel and viable therapeutic strategy for prevention and treatment of Alzheimers disease. Potential approaches to manipulate expression levels of the key amyloiddegrading enzymes are highlighted.

Keywords: Alzheimer's disease, amyloid β-peptide, amyloid precursor protein, angiotensin-converting enzyme, endothelinconverting enzyme, insulysin, neprilysin, matrix metalloproteinase, plasmin, protease

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [212 - 224]
Pages: 13
DOI: 10.2174/156720508783954785
Price: $65

Article Metrics

PDF: 37